108 related articles for article (PubMed ID: 16050268)
1. In silico modelling--pharmacophores and hERG channel models.
Recanatini M; Cavalli A; Masetti M
Novartis Found Symp; 2005; 266():171-81; discussion 181-5. PubMed ID: 16050268
[TBL] [Abstract][Full Text] [Related]
2. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
3. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Cavalli A; Poluzzi E; De Ponti F; Recanatini M
J Med Chem; 2002 Aug; 45(18):3844-53. PubMed ID: 12190308
[TBL] [Abstract][Full Text] [Related]
4. Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations.
Recanatini M; Cavalli A; Masetti M
ChemMedChem; 2008 Apr; 3(4):523-35. PubMed ID: 18224703
[TBL] [Abstract][Full Text] [Related]
5. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for high-affinity block of hERG potassium channels.
Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
[TBL] [Abstract][Full Text] [Related]
8. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
11. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
Coi A; Bianucci AM
J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
[TBL] [Abstract][Full Text] [Related]
12. Prediction of hERG K+ blocking potency: application of structural knowledge.
Aptula AO; Cronin MT
SAR QSAR Environ Res; 2004; 15(5-6):399-411. PubMed ID: 15669698
[TBL] [Abstract][Full Text] [Related]
13. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
14. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines.
Kupershmidt S; Yang IC; Hayashi K; Wei J; Chanthaphaychith S; Petersen CI; Johns DC; George AL; Roden DM; Balser JR
FASEB J; 2003 Dec; 17(15):2263-5. PubMed ID: 14525949
[TBL] [Abstract][Full Text] [Related]
15. Predictive in silico modeling for hERG channel blockers.
Aronov AM
Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
[TBL] [Abstract][Full Text] [Related]
16. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods.
Osterberg F; Aqvist J
FEBS Lett; 2005 May; 579(13):2939-44. PubMed ID: 15893317
[TBL] [Abstract][Full Text] [Related]
17. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
18. A two-state homology model of the hERG K+ channel: application to ligand binding.
Rajamani R; Tounge BA; Li J; Reynolds CH
Bioorg Med Chem Lett; 2005 Mar; 15(6):1737-41. PubMed ID: 15745831
[TBL] [Abstract][Full Text] [Related]
19. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
20. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels.
Diochot S; Loret E; Bruhn T; Béress L; Lazdunski M
Mol Pharmacol; 2003 Jul; 64(1):59-69. PubMed ID: 12815161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
